Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer

<div>(a) The developed nomogram predicting the risk of BCR at 1, 3, and 5 years in PCa patients. (b) Calibration curves of the nomogram to predict BCR at 1 year. (c) Calibration curves of the nomogram to predict BCR at 3 years.</div>

Disease Markers

fig4

Figure 4

Figure 4: Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer 

Figure 4 | Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer 